Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?

Clin Hematol Int. 2023 Aug 28;5(4):1-4. doi: 10.46989/001c.87501. eCollection 2023.

Authors

Ahmed H Al Sharie¹, Balqis M Abu Mousa¹, Ahmad O Alomari¹

Affiliation

¹ Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.

No abstract available

Keywords: Hodgkin lymphoma; Refractory; Relapsed; Ruxolitinib.

Publication types

Review